vs
EXACT SCIENCES CORP（EXAS）与OCEANEERING INTERNATIONAL INC（OII）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是OCEANEERING INTERNATIONAL INC的1.3倍（$878.4M vs $692.4M），OCEANEERING INTERNATIONAL INC净利率更高（5.2% vs -9.8%，领先15.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 3.6%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-76.5M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 1.8%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
奥什科什国际（Oceaneering International）是一家总部位于美国得克萨斯州休斯敦的水下工程及应用技术企业，为海洋、航天及其他特殊作业场景的客户提供定制化工程服务与硬件设备，在极端环境工程领域拥有深厚的技术积累。
EXAS vs OII — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $692.4M |
| 净利润 | $-86.0M | $36.1M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.8% | 5.2% |
| 营收同比 | 23.1% | 3.6% |
| 净利润同比 | 90.1% | -28.3% |
| 每股收益（稀释后） | $-0.45 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $692.4M | ||
| Q4 25 | $878.4M | $668.6M | ||
| Q3 25 | $850.7M | $742.9M | ||
| Q2 25 | $811.1M | $698.2M | ||
| Q1 25 | $706.8M | $674.5M | ||
| Q4 24 | $713.4M | $713.5M | ||
| Q3 24 | $708.7M | $679.8M | ||
| Q2 24 | $699.3M | $668.8M |
| Q1 26 | — | $36.1M | ||
| Q4 25 | $-86.0M | $177.7M | ||
| Q3 25 | $-19.6M | $71.3M | ||
| Q2 25 | $-1.2M | $54.4M | ||
| Q1 25 | $-101.2M | $50.4M | ||
| Q4 24 | $-864.6M | $56.1M | ||
| Q3 24 | $-38.2M | $41.2M | ||
| Q2 24 | $-15.8M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | 19.8% | ||
| Q3 25 | 68.6% | 20.6% | ||
| Q2 25 | 69.3% | 21.3% | ||
| Q1 25 | 70.8% | 20.0% | ||
| Q4 24 | 69.0% | 19.9% | ||
| Q3 24 | 69.4% | 19.3% | ||
| Q2 24 | 69.8% | 18.0% |
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | 9.8% | ||
| Q3 25 | -3.0% | 11.6% | ||
| Q2 25 | -0.3% | 11.3% | ||
| Q1 25 | -13.6% | 10.9% | ||
| Q4 24 | -122.8% | 10.9% | ||
| Q3 24 | -5.6% | 10.5% | ||
| Q2 24 | -3.8% | 9.0% |
| Q1 26 | — | 5.2% | ||
| Q4 25 | -9.8% | 26.6% | ||
| Q3 25 | -2.3% | 9.6% | ||
| Q2 25 | -0.1% | 7.8% | ||
| Q1 25 | -14.3% | 7.5% | ||
| Q4 24 | -121.2% | 7.9% | ||
| Q3 24 | -5.4% | 6.1% | ||
| Q2 24 | -2.3% | 5.2% |
| Q1 26 | — | $0.36 | ||
| Q4 25 | $-0.45 | $1.75 | ||
| Q3 25 | $-0.10 | $0.71 | ||
| Q2 25 | $-0.01 | $0.54 | ||
| Q1 25 | $-0.54 | $0.49 | ||
| Q4 24 | $-4.69 | $0.55 | ||
| Q3 24 | $-0.21 | $0.40 | ||
| Q2 24 | $-0.09 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | $488.8M |
| 股东权益账面价值 | $2.4B | $1.1B |
| 总资产 | $5.9B | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $964.7M | $695.9M | ||
| Q3 25 | $1.0B | $7.0M | ||
| Q2 25 | $858.4M | $7.0M | ||
| Q1 25 | $786.2M | $7.0M | ||
| Q4 24 | $1.0B | $504.5M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — |
| Q1 26 | — | $488.8M | ||
| Q4 25 | — | $487.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $482.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $2.4B | $1.1B | ||
| Q3 25 | $2.5B | $907.7M | ||
| Q2 25 | $2.5B | $842.1M | ||
| Q1 25 | $2.4B | $773.1M | ||
| Q4 24 | $2.4B | $714.3M | ||
| Q3 24 | $3.2B | $698.0M | ||
| Q2 24 | $3.2B | $651.0M |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $5.9B | $2.7B | ||
| Q3 25 | $5.9B | $2.5B | ||
| Q2 25 | $5.8B | $2.3B | ||
| Q1 25 | $5.7B | $2.3B | ||
| Q4 24 | $5.9B | $2.3B | ||
| Q3 24 | $6.7B | $2.4B | ||
| Q2 24 | $6.7B | $2.3B |
| Q1 26 | — | 0.44× | ||
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-76.5M |
| 自由现金流率自由现金流/营收 | 13.7% | -11.1% |
| 资本支出强度资本支出/营收 | 3.6% | 2.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $238.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $221.1M | ||
| Q3 25 | $219.9M | $101.3M | ||
| Q2 25 | $89.0M | $77.2M | ||
| Q1 25 | $30.8M | $-80.7M | ||
| Q4 24 | $47.1M | $128.4M | ||
| Q3 24 | $138.7M | $91.9M | ||
| Q2 24 | $107.1M | $52.6M |
| Q1 26 | — | $-76.5M | ||
| Q4 25 | $120.4M | $190.7M | ||
| Q3 25 | $190.0M | $77.0M | ||
| Q2 25 | $46.7M | $46.9M | ||
| Q1 25 | $-365.0K | $-106.8M | ||
| Q4 24 | $10.7M | $94.5M | ||
| Q3 24 | $112.6M | $67.0M | ||
| Q2 24 | $71.2M | $29.8M |
| Q1 26 | — | -11.1% | ||
| Q4 25 | 13.7% | 28.5% | ||
| Q3 25 | 22.3% | 10.4% | ||
| Q2 25 | 5.8% | 6.7% | ||
| Q1 25 | -0.1% | -15.8% | ||
| Q4 24 | 1.5% | 13.2% | ||
| Q3 24 | 15.9% | 9.9% | ||
| Q2 24 | 10.2% | 4.5% |
| Q1 26 | — | 2.5% | ||
| Q4 25 | 3.6% | 4.6% | ||
| Q3 25 | 3.5% | 3.3% | ||
| Q2 25 | 5.2% | 4.3% | ||
| Q1 25 | 4.4% | 3.9% | ||
| Q4 24 | 5.1% | 4.7% | ||
| Q3 24 | 3.7% | 3.7% | ||
| Q2 24 | 5.1% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | -1.60× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
OII
暂无分部数据
